Live feed08:05:00·43dPRReleaseSCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. InstitutionsSCNX· Scienture Holdings Inc.Health CareOriginal source
